Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 4/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29138425 | 0.84 | FGFR1 (0.43) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL4595441 | 0.81 | FGFR1 (0.41) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL27566188 | 0.79 | FGFR1 (0.44) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL16446911 | 0.79 | FGFR1 (0.47) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL20919715 | 0.77 | FGFR1 (0.46) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL23343373 | 0.76 | FGFR1 (0.44) | FGFR1SLC22A6PDE3ALMNATHRB | |
| SCHEMBL19901038 | 0.76 | FGFR1 (0.44) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL236000 | 0.76 | FGFR1 (0.51) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL24709494 | 0.76 | FGFR1 (0.44) | FGFR1SLC22A6PDE3APDE4DSLC29A1 | |
| SCHEMBL6751072 | 0.76 | FGFR1 (0.44) | FGFR1SLC22A6PDE3APDE4DSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116987495-A | Construction and application of protein membrane macromolecular probe for biological detection | 江南大学 | 2023-11-03 | — | — | CN | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023114963-A1 | COMPOSITIONS AND METHODS FOR SELECTIVELY LABELING SECONDARY AMINES | EMORY UNIVERSITY (US) | 2023-06-22 | — | — | WO | claimed |
| CN-114807328-A | Method for marking and identifying single-base resolution DNA | 浙江大学 | 2022-07-29 | — | — | CN | claimed |
| CN-112301118-B | Method and kit for simultaneously obtaining RNA abundance and active RNA polymerase sites in full transcriptome range | 浙江大学 | 2022-05-13 | — | — | CN | claimed |
| CN-112301118-A | Method and kit for simultaneously obtaining RNA abundance and active RNA polymerase sites in full transcriptome range | 浙江大学 | 2021-02-02 | — | — | CN | claimed |
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | DEPARTMENT OF VETERANS AFFAIRS | 2002-10-31 | — | — | US | claimed |
| EP-1113020-A2 | Nucleosides and oligonucleotides containing boron clusters | EMORY UNIVERSITY (US) | 2001-07-04 | — | — | EP | claimed |
| US-6180766-B1 | OLIGONUCLEOTIDE WITH UNCHARGED INTERNUCLEOTIDE LINKAGE(S) OF 3',5'-O,O-((CARBORAN-1-YL-METHYL)PHOSPHONATE); MADE BY REACTING O-METHYL(O-CARBORAN-1-YL)METHYL PHOSPHONATE WITH PROTECTED NUCLEOSIDE; USE IN BORON NEUTRON CAPTURE THERAPY | DEPARTMENT OF VETERANS AFFAIRS | 2001-01-30 | — | — | US | claimed |
| EP-0731808-A4 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 1997-04-02 | — | — | EP | claimed |
| EP-0731808-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015333-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | claimed |
| US-20240158433-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240140982-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024044741-A2 | EFFICIENT METHOD FOR MAKING HIGHLY PURIFIED 5'-CAPPED OLIGONUCLEOTIDES | TRILINK BIOTECHNOLOGIES, LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4104687-B1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5 -CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2024-01-31 | — | — | EP | disclosed |
| CN-1330634-A | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | GPINIL HOLDINGS INC (US) | 2002-01-09 | — | — | CN | disclosed |
| EP-1163251-A1 | N-ACYLPHOSPHORAMIDITES AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | disclosed |
| US-20010044529-A1 | Thermolabile phosphorus protecting groups, associated intermediates and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-11-22 | — | — | US | disclosed |
| WO-2000056749-A1 | N-ACYLPHOSPHORAMIDITES AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | NUDT1, NTPCR, NAMPT | SLC2A1 697/4885FGFR1 1690/4885SLC22A6 271/4885 |
| US-20240140982-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | SLC2A1 4812/4885FGFR1 4688/4885SLC22A6 3638/4885 |
| US-20010044529-A1 | Thermolabile phosphorus protecting groups, associated intermediates and methods of use | POLR2H, POLL, POLR1A | SLC2A1 2019/4885FGFR1 1128/4885SLC22A6 2574/4885 |
| US-20240158433-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | RNGTT, RNMT, NT5C3B | SLC2A1 4812/4885FGFR1 4688/4885SLC22A6 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.